🔬 PubMed Lab
日本語で入力するだけで、PubMed の英語論文を検索できるリサーチアシスタントです。
卒論・研究テーマ探し、興味のある論文を効率よく見つけられます。
🎓 卒論・修論テーマを AI が提案
この 5 本の論文を俯瞰して、あなたが実際に卒論・修論で研究できるテーマを 3 つ提案します。
📖 このサイトの解説記事から (日本語で読める)
PubMed Trivia が過去に取り上げた論文を日本語で解説している記事です。
🔍 PubMed の検索結果
-
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD). However, the probability of low semaglutide doses, an agonist with higher potency and affinity for GLP-1R, to attenuate alcohol-related responses in rodents and the underlying neuronal mechanisms is unknown. In the intermittent access mode…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
This study evaluated the effect of once-weekly semaglutide 2.4 mg on 2-year control of eating. In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity. …
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings. To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD). This was a pha…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
The emerging role of glucagon-like peptide 1 in binge eating.
Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycem…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.
Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addi…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians.
Metabolic syndrome is a cluster of cardiovascular risk factors (central obesity, hypertension, dyslipidemia, and insulin resistance) that affects between 12.5% and 31.4% of adults worldwide. It correlates with increased risks of cardiovascular disease, diabetes, cancer, and overall mortality in a dose-dependent fashion. This review aims to provide primary care clinicians an updated review of the e…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetit…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
BackgroundAlcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.MethodsIn a randomized, doub…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review.
The roles of metabolic signals, including Glucagon-like peptide 1 (GLP-1), have been implicated in multiple domains outside metabolic regulation. There is a growing interest in repurposing Glucagon-like peptide 1 receptor agonists (GLP-1RAs) as therapeutics for motivation and reward-related behavioural disturbances. Herein, we aim to systematically review the extant evidence on the potential effec…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」
-
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing. GLP…
💬 論文と壁打ち β 残り 3 / 3 回 (今日)Abstract の内容だけを根拠に答えます。医療助言はしません。abstract に無い事実は「記載なし」と返します。質問例: 「要点を3つ教えて」「結論の限界は?」「N数と統計手法は?」「反論できる可能性は?」